April 30, 2014 — Johnson & Johnson’s Ethicon unit, the world’s biggest manufacturer power morcellators, has halted global sales and promotion because the popular surgical tools could spread cancer.
J&J and Ethicon will stop selling the following morcellators:
- Gynecare Morcellex
- Morcellex Sigma
- Gynecare X-Tract
According to the Wall Street Journal, J&J purchased FemRx and its “Diva” morcellator in 1998. By 2011, they owned a owned a 72% share of the power morcellator market.
On April 17, the U.S. Food and Drug Administration (FDA) warned that power morcellators should not be used in hysterectomies or surgery to remove uterine fibroids. About 1 in 350 women who undergoes this procedure actually has uterine sarcoma. When the morcellators grind up fibroids, they can leave behind tiny pieces of tissue and spread cancer throughout a woman’s abdomen and pelvis.
Ethicon is facing at least one lawsuit filed by a woman who died of metastatic leiomyosarcoma at the age of 53, one year after undergoing a hysterectomy with a power morcellator.
Do I have a Morcellator Cancer Lawsuit?
The Schmidt Firm, PLLC is currently accepting power morcellator induced injury cases in all 50 states. If you or somebody you know has been injured by cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Medical Device Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.
The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs' law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm's reputation for providing personal attention to each and every client we represent.
